#41bb - Twitter Hashtag

over 1 year ago

From the January issue:Combined #KRAS Inhibition and #immunotherapy Generates Durable Complete Responses in an Autochthonous PDAC Model https://t.co/wMx0vetNVr By Yonghong Liu, @RonDePinho and colleagues @MDAndersonNews #PancreaticCancer #CXCR1/2 #LAG3 #41BB

CD_AACR's tweet photo. From the January issue:Combined #KRAS Inhibition and #immunotherapy Generates Durable Complete Responses in an Autochthonous PDAC Model https://t.co/wMx0vetNVr

By Yonghong Liu, @RonDePinho and colleagues @MDAndersonNews #PancreaticCancer #CXCR1/2 #LAG3 #41BB https://t.co/fu6o5SkZMX

0

21

8

5

7K

Elizabeth McKenna @ElizSMcKenna

almost 2 years ago

Now online in @CD_AACR: Combined #KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model - by Yonghong Liu, @RonDePinho and colleagues https://t.co/UzvK0rUTER @MDAndersonNews #PancreaticCancer #CXCR1/2 #LAG3 #41BB

ElizSMcKenna's tweet photo. Now online in @CD_AACR: Combined #KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model - by Yonghong Liu, @RonDePinho and colleagues https://t.co/UzvK0rUTER @MDAndersonNews #PancreaticCancer #CXCR1/2 #LAG3 #41BB https://t.co/mLwzNOmMEC

1

89

24

20

9K

Carlos Luri @carlosluri_

over 3 years ago

Check out our latest Review on @CD_AACR about CD137 (4-1BB)-based Cancer Immunotherapy on its 25th Anniversary. Truly grateful to have made the illustrations of it. Congrats to @DrIgMelero and team. #41BB #CD137 #CancerDiscovery #CancerImmunotherapy . https://t.co/qoHhQXwKPE

0

8

3

1

1K

I-Mab Biopharma @IMabBiopharma

over 4 years ago

Sharing our #2021highlights: Moving 2 bispecific antibodies into clinic. TJ-CD4B is the first CLDN18.2 x #41BB #bispecific #antibody of its kind to enter clinical stage in China. Lead bispecific antibody assets, TJ-CD4B and TJ-L14B, at forefront of 4-1BB bispecific development.

IMabBiopharma's tweet photo. Sharing our #2021highlights: Moving 2 bispecific antibodies into clinic. TJ-CD4B is the first CLDN18.2 x #41BB #bispecific #antibody of its kind to enter clinical stage in China. Lead bispecific antibody assets, TJ-CD4B and TJ-L14B, at forefront of 4-1BB bispecific development. https://t.co/9BN8L0PhuS

0

2

0

Cancer Immunology Research @CIR_AACR

over 4 years ago

This study IDs #CD137 (#41BB) as an actionable target for enhancing #NKcell persistence and function by counteracting #TGFβ suppression. Read more here! https://t.co/Pyk0eRscMc @AMuntasell @aecc_es @IMIM_research @UABBarcelona @WorldwideCancer @hospitaldelmar

CIR_AACR's tweet photo. This study IDs #CD137 (#41BB) as an actionable target for enhancing #NKcell persistence and function by counteracting #TGFβ suppression. Read more here! https://t.co/Pyk0eRscMc
@AMuntasell @aecc_es @IMIM_research @UABBarcelona @WorldwideCancer @hospitaldelmar https://t.co/wayOKjozG6

0

3

2

1

0

Bernard A Fox @BernardAFox

over 4 years ago

@DrLizJaffee #pancreaticcancer Guru @hopkinskimmel @HopkinsMedicine great talk! Reviews findings of #immunotherapy trials/lots of unpublished data suggesting triplet of #cancer #vaccine + #41BB + #PD1 give more activ T cells @FondMelanoma #IOBridge2021 @sitcancer @PAscierto

BernardAFox's tweet photo. @DrLizJaffee #pancreaticcancer Guru @hopkinskimmel @HopkinsMedicine great talk! Reviews findings of #immunotherapy trials/lots of unpublished data suggesting triplet of #cancer #vaccine + #41BB + #PD1 give more activ T cells @FondMelanoma #IOBridge2021 @sitcancer @PAscierto https://t.co/9iWW3rnerm

0

3

1

0

Numab Therapeutics @Numab_Tx

about 5 years ago

Our Series C secured in May will boost our lead program in multiple cancer indications. We took the time to explain the concept of targeting #41bb and #pdl1 and why monovalent binding, tumor cell anchoring, and tailored affinities matter in this new video: https://t.co/U1JWYrjmEc

Numab_Tx's tweet photo. Our Series C secured in May will boost our lead program in multiple cancer indications. We took the time to explain the concept of targeting #41bb and #pdl1 and why monovalent binding, tumor cell anchoring, and tailored affinities matter in this new video: https://t.co/U1JWYrjmEc https://t.co/uy39hKnP65

0

3

0

1stOncology @1stOncology

about 5 years ago

#PierisPharmaceuticals and #BostonPharmaceuticals Enter into an Exclusive Worldwide Product License for #PRS342, a #41BB #GPC3 #ImmunoOncology #Bispecific $PIRS https://t.co/0an1LKYnso

0

1

0

Chris Shepherd @ChrisJ_Shepherd

over 5 years ago

Really excited to anounce first subject dosed with F222 (CD137/PD-L1)!! #fstar #41bb #cd137 #pdl1 #immunotherapy #oncology #clinicaltrial https://t.co/Cg4QxylUv3

0

1

0

1stOncology @1stOncology

over 5 years ago

#Medigene's #Pd1-#41bb Switch Receptor Effectively Enhances #TCRTCells To Fight #SolidTumors $MDG1 https://t.co/QZqSMXjoBa

0

3

1

0

Lotte Lindgreen Eriksen @eriksen_lotte

almost 6 years ago

Finally defended my research year thesis about #41BB in #alcoholichepatitis 👩🏼‍🔬 Thank you to my supervisors and colleagues from @HepGasDK and @AarhusUni

eriksen_lotte's tweet photo. Finally defended my research year thesis about #41BB in #alcoholichepatitis 👩🏼‍🔬 Thank you to my supervisors and colleagues from @HepGasDK and @AarhusUni https://t.co/fr9lq46cQ0

2

5

0

1stOncology @1stOncology

about 6 years ago

#Medigene reported insights from preclinical studies on its #PD1-#41BB switch receptor at the #AACR20 $MDG1 https://t.co/m76qqcIf1C

0

2

0

Paul D. Rennert @PDRennert

over 6 years ago

thinking about T cell stimulation so updated agonist antibodies to TNFRSF proteins ... hmmmm #OX40 #41BB #GITR $AZ $RHHBY $PFE $BMY $MRK

PDRennert's tweet photo. thinking about T cell stimulation so updated agonist antibodies to TNFRSF proteins ... hmmmm

#OX40 #41BB #GITR $AZ $RHHBY $PFE $BMY $MRK https://t.co/yxJafTtRsf

1

5

3

0

Bio X Cell @invivoantibody

over 6 years ago

@nature published Optimization of 4-1BB antibody for #cancer #immunotherapy by balancing agonistic strength with FcγR affinity. Learn more and have access to the full article at the link below. https://t.co/xYKeEJzBqu #Bio_X_Cell #invivoantibody #41BB

invivoantibody's tweet photo. @nature published Optimization of 4-1BB antibody for #cancer #immunotherapy by balancing agonistic strength with FcγR affinity.
Learn more and have access to the full article at the link below.
https://t.co/xYKeEJzBqu
#Bio_X_Cell #invivoantibody #41BB https://t.co/uyBMxXt8Kv

0

2

1

0

ACIR

@ACIR_org

about 7 years ago

All the T cell costimulation, none of the liver toxicity. #41BB #Tcell #costimulation @Roche Read our summary at https://t.co/USGFzC9En9. Original study published in @ScienceTM

ACIR_org's tweet photo. All the T cell costimulation, none of the liver toxicity. #41BB #Tcell #costimulation @Roche Read our summary at https://t.co/USGFzC9En9. Original study published in @ScienceTM https://t.co/zDOBjujXG2

0

2

4

0

Naveen Pemmaraju, MD @doctorpemm

about 7 years ago

#ASCO19. Very nice comparison slide by Dr J Abramson among 3 CAR-T constructs in R/R lymphoid Malignancies. #CD28 #41BB #leusm #lymsm #ImmunoOnc

doctorpemm's tweet photo. #ASCO19. Very nice comparison slide by Dr J Abramson among 3 CAR-T constructs in R/R lymphoid Malignancies. #CD28 #41BB #leusm #lymsm #ImmunoOnc https://t.co/cuYvF9wIIF

0

7

4

0

John Castle @joccastle

about 7 years ago

At #CIMT2019, Pablo Umaña (Roche) stresses need for #41BB (#CD137) treatment in #cancerimmunotherapy. @Agenus_Bio

0

6

2

1

0

Titan V @titan_v16

over 7 years ago

$APVO #AACR abstract number 2 (preclinical) #CD137 #41BB #bispecifics #solidtumors https://t.co/QmZHYs7nMr

0

3

2

0

Bernard A Fox @BernardAFox

over 7 years ago

*SLIDE SET 4* Dr Greg Delgoffe @DelgoffeLab @UPMC talks @agon_ox #DeepDive19 /oxidative metabolism as a predictive biomarker for #PD1 #immunotherapy & therapeutic target/ clinical trial open #41BB #ImmunoOnc19 #melanoma #FinishCancer @SU2C #Maui

BernardAFox's tweet photo. *SLIDE SET 4* Dr Greg Delgoffe @DelgoffeLab @UPMC talks @agon_ox #DeepDive19 /oxidative metabolism as a predictive biomarker for #PD1 #immunotherapy & therapeutic target/ clinical trial open #41BB #ImmunoOnc19 #melanoma #FinishCancer @SU2C #Maui https://t.co/qXncbDsGiH

0

2

0

Bernard A Fox @BernardAFox

over 7 years ago

* SLIDE SET 2* Dr Anthony Vella Immunology Chair @UConn talks @agon_ox #DeepDive19 /Explains how Dual Anti- #OX40 & #41BB (Orthomab) May be working/ will be interested 2 see results of @pfizer combo clinical trial? @sitcancer @ASCO #ImmunoOnc19 #Finishcancer #maui

BernardAFox's tweet photo. * SLIDE SET 2* Dr Anthony Vella Immunology Chair @UConn talks @agon_ox #DeepDive19 /Explains how Dual Anti- #OX40 & #41BB (Orthomab) May be working/ will be interested 2 see results of @pfizer combo clinical trial? @sitcancer @ASCO #ImmunoOnc19 #Finishcancer #maui https://t.co/mvoOWsEoj7

1

3

0

1

0

Top Tweets for #41bb

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users